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Abstract: Cyclosporine (CsA), a member of the family of calcineurin inhibitors, is a cornerstone 
of the immunosuppressive treatments used after organ transplantation. However, it exhibits 
significant toxicity, including nephrotoxicity and increased cardiovascular risk factors. CsA 
withdrawal has been used as a strategy to improve renal allograft function and other CsA-related 
toxicities. In order to maintain adequate immunosuppression levels, sirolimus may be used in 
association with CsA withdrawal. Sirolimus is a member of the mammalian target of rapamycin 
(mTOR) family. It presents a good immunosuppressive efficacy associated with antiproliferative 
actions. Early withdrawal of CsA with sirolimus is associated with a significant improvement of 
renal function. Despite numerically a higher incidence of acute rejection episodes, this maneuver 
seems also to be associated with a better allograft survival in the long-term, and improvement 
of renal histology and blood pressure. However, CsA withdrawal is only feasible in a selected 
population. Furthermore, the use of sirolimus is associated with other side-effects including 
lipid abnormalities, abnormal liver tests, and thrombocytopenia. Other studies are mandatory 
to define the population who can benefit from this maneuver. Finally, complete CsA avoidance 
has been already reported and is currently under clinical investigation. 
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Introduction
Since the early 1980s, standard care for immunosuppression in transplant recipients 
has involved the use of calcineurin inhibitors (CNIs) such as cyclosporine (CsA) and 
tacrolimus (TAC). CsA inhibits T-cell activation pathways which require a rise in 
intracellular-free calcium concentration, thus reducing the production of interleukin-2 
(IL-2) (Wiederrecht et al 1993). CsA binds specifically and with high affinity to a family 
of receptors called cyclophilins ( Erlanger 1992; Schreiber 1992). This drug-receptor 
complex inhibits the activation of calcineurin phosphatase which dephosphorylates 
and activates the nuclear factor of activation of T cells (NF-AT). NF-AT increases 
transcription of IL-2. Inhibition of IL-2 transcription by CsA therefore stops the 
proliferation and activation of helper and cytotoxic T cells (Suthanthiran et al 1996). 
The results of several studies suggest that the use of CsA after renal transplantation 
reduces the number of acute rejection episodes and enhances short-term allograft 
survival (The Canadian Multicentre Study Group 1986). However, most of the benefit 
appears to result from a decrease in the number of acute rejections during the first 
months after transplantation. CsA is indeed associated with significant nephrotoxic 
side-effects as well as other side-effects in the short and long term (Myers et al 1988; 
Schorn et al 1991; Fioretto et al 1995; Bennett et al 1996; Goldstein et al 1997). 
In both experimental models and human clinical studies, it has been well established 
that CsA produces dose-dependent, acute, and reversible vasoconstriction of renal 
arterioles. CsA-induced acute renal failure may occur as early as a few days or months 
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after the initiation of therapy (Flechner et al 1983). The 
clinical manifestations of renal arteriolar vasoconstriction or 
acute renal dysfunction include reduction of the glomerular 
filtration rate, hypertension, hyperkaliemia, tubular acidosis, 
increased reabsorption of sodium, and oliguria (Remuzzi and 
Perico 1995). The adverse effects on renal hemodynamics are 
thought to be directly related to blood CsA concentrations. 
The precise mechanism and the mediators involved in these 
adverse effects and implicated in the alteration of renal 
hemodynamics have yet to be identified. Many mediators 
such as endothelin, thromboxane A2, renal prostaglandins, 
and nitric oxide are probably implicated (Bunchman and 
Brookshire 1991; Lanese and Conger 1993; Bobadilla et 
al 1994). 
Chronic progressive nephrotoxicity is the major toxic 
effect in the long term and is associated with mild-to- 
moderate renal dysfunction. The transition from acute 
hemodynamic changes to chronic injury has not been clearly 
established. Studies based on biopsies of experimental   
models, patients with autoimmune diseases, and extrarenal 
solid organ transplants have demonstrated the specific 
pathological and morphological changes occurring in 
CsA-induced chronic progressive nephropathy (Palestine 
et al 1986; Dische et al 1988; Nizze et al 1988; Mihatsch 
et al 1995). Histologically, the latter is characterized by 
arterial wall destruction, myointimal necrosis, and gradual 
narrowing of the arterial lumen. It is also associated 
with tubulointerstitial fibrosis with a striped pattern. Its 
pathogenesis is unclear. Low-grade chronic ischemia due to 
continuous renal vasconstriction may be an important cause. 
However, in an experimental model in salt-depleted rats, no 
clear relationship between glomerular hemodynamics and the 
development of histological lesions was found (Elzinga et al 
1993). Other experiments led to the conclusions that the renin 
angiotensin system is activated intrarenally by CsA, which 
leads to the deposition of excess matrix protein by stimulating 
its production and/or diminishing its breakdown (Shihab et al 
1997). Transforming growth factor β-1 (TGF-β1) has been 
suggested to play a role in causing chronic progressive CsA-
induced nephropathy, by acting as a profibrotic cytokine.
The incidence of this nephropathy after renal trans-
plantation is difficult to evaluate. Several processes can lead 
to tubulointerstitial fibrosis and structural and functional 
deterioration of the kidney. These include chronic rejection, 
hypertension, hyperglycemia, hyperlipidemia, recurrence of 
underlying disease, and aging. The major drawback of many 
studies is the absence of renal histology. Nankivell et al (2003) 
reported recently a very important approach that enlightens 
the natural history of chronic allograft nephropathy. In a 
prospective study among 120 consecutive patients with type 
1 diabetes mellitus who received either a kidney–pancreas 
transplant (n = 119) or a kidney transplant alone (n = 1). Three 
or more sequential kidney-transplant–biopsy specimens 
were available from all these patients. During the first year 
after transplantation, mild chronic allograft nephropathy was 
present in 94.2% of patients associated with ischemic injury, 
and clinical and subclinical rejection. Beyond 1 year, a later 
phase of chronic allograft nephropathy was characterized 
by microvascular and glomerular injury. However, chronic 
rejection, ie, immunological process, was uncommon but 
nephrotoxicity was almost universal at 10 years even in grafts 
with excellent early histologic findings. CNI nephrotoxicity 
was the major cause of late histologic injury and ongoing 
decline in renal function.
Another approach to evaluating the incidence of chronic 
allograft CsA-induced nephropathy is to examine the 
occurrence of this complication among nonrenal transplant 
recipients (Ojo et al 2003) or in autoimmune disease 
(Vercauteren et al 1998). After heart transplantation, a 10% 
prevalence of CNI-induced end-stage renal failure was 
reported after 5–10 years of immunosuppressive therapy 
(Greenberg et al 1990). After liver transplantation, in 305 
CsA-treated patients, renal dysfunction, defined as a serum 
creatinine level greater than 140 mmol/L, occurred in 50% 
of patients, and 15% needed renal support (O’Grady et 
al 2002). When renal biopsies were performed in liver-
transplant recipients because of chronic renal impairment, 
chronic CsA nephrotoxicity was present in about one third 
of these biopsies. In auto-immune diseases, Vercauteren et 
al (1998) reported a difference of 20.9% between the risk 
of developing nephrotoxicity with CsA therapy and with an 
alternative therapy. 
CsA has been associated also with other toxicities other 
than renal. The most important is the worsening of many 
cardiovascular risk factors (Miller 2002). Thus, CsA is 
associated with hypertension: its incidence among renal 
transplant recipients was 50% before the CsA era and is now 
reported to be higher than 80%. Hyperlipemia is another 
common cardiovascular risk factor in patients treated with 
CsA. Since cardiovascular disease is the most frequent cause 
of death, and is also a cause of allograft failure, these issues 
are becoming increasingly important, as the improvement 
of immunological complications is observed after renal 
transplantation.
The balance between preventing immunological allograft 
failures and managing nephrotoxicity is still an unsolved international Journal of Nanomedicine 2006:1(3) 271
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issue. In order to include the nonimmunological components 
of late graft loss or renal dysfunction after kidney 
transplantation, especially drug-induced nephrotoxicity, the 
term of “chronic rejection” has been replaced by “chronic 
allograft nephropathy”. In an attempt to improve the long-
term survival of grafts and patients, and to avoid CsA-related 
adverse effects, conversion from CsA to nonnephrotoxic 
immunosuppressive drugs has been extensively reported 
in the literature since 1988. The recent introduction of new 
immunosuppressive drugs such as mycophenolate mofetil 
(MMF) or sirolimus (SRL) has strenghtened the case for 
minimizing the use of CsA. The main strategies for reducing 
potential CsA-induced nephrotoxicity consist of sparing CsA 
in induction regimens from the day of transplantation or early 
CsA withdrawal. 
Because of its specific properties and the potential 
synergy in CsA nephrotoxicity, early CsA withdrawal has 
been explored using SRL treatment. I will focus this review 
on the reason and aims of this approach and the reports on 
both short- and long-term results after this maneuver.
Mechanism of action of SRL
SRL, an antifungal macrolide, displays potent antiprolifera-
tive activities that produce antitumor and immunosuppressive 
effects. The search for the mechanism of action of SRL led 
to the discovery of a protein, target of rapamycin (TOR). 
TOR is a serine–threonine kinase that plays a critical role in 
growth factor and nutrient-sensitive signaling pathways that 
regulate cell growth, integrating signals from the amino acid 
supply and cellular energy state, and transducing stimuli from 
a variety of hormonal and cytokine receptors. These actions 
control autophagy, actin cytoskeletal organization, mRNA 
transcription, protein turnover, and, particularly, initiation 
of protein translation (Abe and Thomson 2003; Harris and 
Lawrence 2003; Lekmine et al 2004).
Structure of TOr
TOR is a member of the phosphatidylinositol 3-kinase (PI3K) 
superfamily. PI3K has the unique ability to phosphorylate 
carbon 3 of membrane phosphatidylinositols. TOR is highly 
conserved from yeast to mammals: yeast TOR1 and TOR2 
show 42% and 45% identity, respectively, with the nucleotide 
sequence of the human genes, and TOR protein (2549 amino 
acids long) displays 95% identity among humans, mice, and 
rats (Harris and Lawrence 2003; Bjornsti and Houghton 
2004; Mayer et al 2004). Mammalian TOR (mTOR) is a 
289-kd serine–threonine kinase. The FKBP12-rapamycin-
binding domain of mTOR is a four-helix bundle having 
short underhand connections that loop, positioning the NH2-
terminus and COOH-terminus close to each other. Sirolimus 
forms a complex, simultaneously binding two hydrophobic 
pockets: one in the isomerase FKBP12 at high affinity (Choi 
et al 1996) at Ser
2035, thereby joining FKBP12 and TOR. SRL 
is almost completely buried between the macromolecules in 
the ternary complex. The SRL bridge is critical because, in 
its absence, the two proteins interact with each other only to 
a limited extent. Mutations of Ser
2035 to Thr render mTOR 
resistant to the actions of SRL-FKBP12, probably owing to 
the greater bulk of the substituent residue. The formation of 
the ternary complex with FKBP12-rapamycin may inhibit 
TOR kinase activity either directly or by blocking access to 
substrate partner proteins. 
enzymatic activity of TOr
TOR activation requires upregulation of PI3K and its 
downstream effector, the serine–threonine Akt. The PI3K 
pathway not only integrates receptor tyrosine kinase signaling 
but also the apoptotic network. Akt phosphorylates multiple 
downstream effectors that stimulate cell cycle progression, 
alter metabolism, produce changes in mRNA translation, 
and ultimately control cell death (Abe and Thomson 2003; 
Beugnet et al 2003; Kristof et al 2003; Caldarola et al 
2004) by decreasing transcription of proapoptotic genes 
through inhibition of forkhead transcription factors. Akt 
thus increases cell size, suppresses apoptosis, inactivates 
cell cycle inhibitors, and induces cyclin and cytokine 
gene expression. In T and B cells, Akt activation, which 
follows antigen receptor engagement, is greatly boosted by 
costimulation (Edinger et al 2003; Manning and Cantley 
2003). Akt directly phosphorylates TOR at Ser
2448, thereby 
dissociating its complex with the proteins coded by the genes 
mutated in tuberous sclerosis complex (TSC)–hamartin 
(TSC1, Mr < 130 000) and tuberin (TSC2, Mr < 200 000) 
(Gao et al 2002; Inoki et al 2002; Potter et al 2002; Jefferson 
and Kimball 2003). 
mTOR inhibitors cause cell cycle arrest in the G1-phase. 
mTOR is part of a multisubunit complex that contains the 
regulatory associated protein of mTOR (RAPTOR) and a 
protein denoted as GssL (G protein  subunit-like protein) 
(Kim et al 2003; Stromberg et al 2004; Tokunaga et al 2004). 
RAPTOR links TOR to p70 ribosomal S6 kinase (S6K1) or to 
an inhibitor of eukaryotic translation initiation factor 4E–eIF-
4E binding protein 1(4E-BP1also known as PHAS) through 
a TOR signaling (TOS) motif (Yonezawa et al 2004) in the N 
terminus of S6K1or C terminus of 4E-BP1. On stimulation 
by insulin, other growth factors, cytokines, or nutrients international Journal of Nanomedicine 2006:1(3) 272
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(Bjornsti and Houghton 2004), mTOR phosphorylates at 
least two regulators of translational protein synthesis: S6K1 
and 4E-BP. By promoting phosphorylation of S6, mTOR 
activates S6K1.
Phosphorylation of the S6 subunit of 40S ribosomes 
follows mitogenic stimulation, leading to initiation of protein 
translation by mRNAs possessing a 5-terminal oligopyear 
imidine tract (5-TOP) (Tabancay et al 2003; Lekmine et 
al 2004), including p70 ribosomal proteins and eukaryotic 
elongation factor 2 (Kim and Chen 2000; Gstaiger et al 2003; 
Sehgal 2003). All known ribosomal proteins and several 
abundant elongation factors are encoded by TOP messages 
(Zhu et al 2003; Caldarola et al 2004).
mTOR-dependent phosphorylation of serine Ser
65 and 
N-terminal Thr
37, Thr
46, and Thr
70 in 4E-BP1 cleaves 4E-
BP1 from the translational activator eIF-4E (Ferguson et 
al 2003). After a final phosphorylation event at Ser65, 4E-
BP1dissociates from eIF-4E, an action that reconstitutes the 
translationally competent initiation factor (eIF-4F), resulting 
in translation of a subset of capped mRNAs, which contain 
highly structured 5-untranslated regions that encode proteins 
involved in G1- to S-phase progression (Boulay et al 2004). 
In favorable growth conditions, mTOR phosphorylates 4E-
BP1, which binds to and inhibits the action of the mRNA 
5 cap recognition element of the translation initiation 
complex protein eIF-4E (Jefferson and Kimball 2003). The 
dissociation of eIF-4E thus enhances the translation initiation 
complex (Raught et al 2004), allowing it to associate with 
eIF-4G to initiate translation (Tang et al 2002; Lekmine et 
al 2003; Browne and Proud 2004). mTOR phosphorylates 
Stat3, which enhances transcription of factors c-myc and 
cyclin D1, and catalyzes activation of cyclin-dependent 
kinases by releasing the inhibitory factor p27kip1. These 
effects promote cell cycle progression, resulting in activation 
of RNA polymerases I and II as well as polyphosphorylation 
of retinoblastoma protein.
TOr regulation of cell survival
Nonactivated mature T cells in the G0 phase of the cell 
cycle require 3 signals for full activation. The first signal 
is delivered by the binding of presented alloantigen to the 
T-cell antigen receptor. The second signal is generated by 
the interaction of CD28–B7 and CD40-CD40 ligand and 
other less well understood molecules that couple antigen-
presenting elements to T cells. These two signals cause T 
cells to produce cytokines that act in paracrine and autocrine 
fashion to bind specific high-affinity receptors and drive 
cells to enter the G1 phase, the third signal, to prepare for 
the S phase, leading to nucleic acid synthesis, cell division, 
and clonal expansion (Abraham and Wiederrecht 1996; 
Slavik et al 2004). In T cells, mTOR participates in protein 
translation following sustained upregulation of cytokine 
transcription by CD28 engagement. Coengagement of the 
T-cell receptor by major histocompatible complex peptides 
and CD28 by B7 ligands provides the requisite combination 
to promote survival and initiate cytokine production (Abe and 
Thomson 2003). Subsequently, these cytokines, particularly 
interleukin-2, provide a strong proliferation and survival 
signal that enables T-cell clonal expansion. Thus, in T cells 
and also in B cells, stimulation via the antigen receptor and 
other mitogenic sites causes phosphorylation and activation 
of S6K1 in a PI3K dependent manner (Abe and Thomson 
2003; Deane and Fruman 2004).
Biochemistry of mTOr inhibitors
SRL inhibits the catalytic activity of mTOR by virtue 
of its high-affinity binding to the isomerase FKBP12- 
rapamycin, thereby preventing the association of RAPTOR 
with mTOR. This association reduces mTOR-catalyzed 
phosphorylation of RAPTOR-dependent S6K1 and 4EBP1 
but not RAPTOR-independent substrates. Further, SRL 
blockade of mTOR accelerates the turnover of cyclin D1, 
leading to a deficiency of active CDK4–cyclin D1 complexes, 
all of which may cause G1-phase arrest (Stromberg et al 
2004). CD28-mediated degradation of I B and translocation 
of c-Rel to the nucleus is also inhibited by SRL (Lai and 
Tan 1994). 
Increased nephrotoxicity after 
simultaneous use of SRL and CNIs
The different renal adverse events observed in clinical 
practice and suggested to be related to SRL therapy include 
potentiation of CNI nephrotoxicity, prolongation of delayed 
graft function when used in de novo patients, proteinuria, 
and acute nephrotoxicity.
SrL enhances CNis nephrotoxicity
Food and Drug Administration (FDA) and European 
Agency for the Evaluation of Medicinal Products (EMEA) 
registration trials have shown that in combination with CsA, 
SRL significantly lowered acute rejection incidence when 
compared with azathioprine (AZA), MMF, or placebo. 
However, impaired renal function was demonstrated in the 
CsA–SRL–steroid group compared with CsA–AZA–steroid, 
CsA–placebo–steroid, or CsA–MMF–steroid groups. international Journal of Nanomedicine 2006:1(3) 273
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In a phase III trial designed to investigate the impact of 
the addition of SRL (2 or 5 mg daily), compared with AZA, 
to a CsA and prednisone regimen in renal transplant patients, 
Kahan (2000) demonstrated that combination therapy 
with CsA and SRL resulted in significantly higher serum 
creatinine concentrations and lower creatinine clearance 
than in patients treated with CsA and AZA after 6 and 12 
months. Whereas acute rejection rates were lower in the two 
SRL groups than in the AZA group, calculated creatinine 
clearances were 62.29 (p < 0.01 vs AZA), 59.15 (p < 0.001 
vs AZA), and 68.78 mL/min at 6 months and 61.95 (p < 0.05 
vs AZA), 55.48 (p < 0.001 vs AZA), and 67.51 mL/min at 1 
year in the 2 mg/day SRL, 5 mg/day SRL and AZA groups 
respectively. In a similar double-blind, multicenter, placebo-
controlled study, MacDonald (2001) investigated the ability 
of 2 different doses of SRL (2 mg and 5 mg) to prevent acute 
rejection when added to a regimen of CsA and corticosteroids 
after renal transplantation. Significant differences among the 
treatment groups in mean creatinine clearance values were 
observed at month 3 (p = 0.006) and month 6 (p = 0.041). At 
month 3, the 5 mg/day SRL group had lower mean glomerular 
filtration rate values (54.98 mL/min) than either the 2 mg/day 
SRL group (59.07 mL/min, p = 0.05) or the placebo group 
(61.12 mL/min, p < 0.01). A similar difference was observed 
between the 5 mg/day SRL group and the placebo group at 
month 6 (56.42 vs 62.58 mL/min, p = 0.05) (MacDonald 
2001). These results are now confirmed after 24 months 
of follow-up (Kahan 2003). These studies resulted in the 
EMEA recommendation to withdraw CsA from SRL at 
3 months. In a retrospective study including 23 016 renal 
transplant patients (between January 1988 to July 2003), 
Meier-Kriesche et al (2004) have compared the outcomes of 
patients who were initially treated with CsA+MMF with those 
initially treated with CsA+SRL. Multivariate analysis showed 
that CsA+SRL was associated with a significantly increased 
risk for graft loss, death-censored graft loss, and decline in 
renal function (HR = 1.22, p = 0.002; HR = 1.22, p = 0.018; 
HR = 1.25, p < 0.001). Finally, in nonrenal transplantation, a 
prospective study has compared everolimus, another mTOR 
inhibitor, with AZA in 634 heart transplant patients treated 
with CsA and steroids (Eisen et al 2003). Patients receiving 
the association CsA and everolimus experienced a significant 
increase in serum creatinine levels, beginning as early of 
the first month post-transplantation, whereas CsA blood 
concentrations were similar in the two groups.
experimental data and possible 
mechanisms
There is no evidence in the literature that therapeutic doses 
of SRL alone may cause significant nephrotoxicity in most 
animal studies. Nevertheless, at high concentrations (3 mg/
kg/day) in rats, SRL caused renal dysfunction, tubular 
collapse, vacuolization, nephrocalcinosis, and magnesium 
wasting (Andoh, Burdmann, et al 1996). Several animal or 
in vitro models have shown that SRL, when used in specific 
situations, such as in association with CNI or after ischemic 
damage, induces functional or morphological alterations of 
the kidneys.
Nephrotoxic interaction between SrL and CNis
Andoh et al studied the effects of combining CsA and SRL 
on renal structure and function in a rat model of chronic 
CsA nephropathy. Associated with placebo, or various CsA 
dose, SRL at a subtherapeutic dose of 0.1 mg/kg worsened 
glucose metabolism and potentiated chronic nephrotoxicity 
induced by CsA at 8 mg/kg in terms of both renal function 
and structural injury (Andoh, Lindsley, et al 1996). In another 
study, Sprague-Dawley rats were treated with either CsA 
(15 mg/kg/day), TAC (3 mg/kg/day), or SRL (0.4 mg/kg/day) 
monotherapy or in different combinations over a 2-week 
period in order to examine the effects on glomerular function, 
as well as the possible morphological changes in the kidneys 
(Nielsen et al 2003). The greatest glomerular filtration rate 
(GFR) deteriorations were observed in the groups where 
CsA was associated with either SRL or TAC. Interestingly, 
CsA whole-blood concentrations did not differ significantly 
between the two groups treated or not with SRL. The result 
indicates that SRL has a pronounced synergistic nephrotoxic 
effect on the GFR and on a number of morphological 
fibrotic changes when combined with CsA. These results 
were confirmed more recently in a similar animal model 
of chronic CsA nephrotoxicity (Shihab et al 2004a). When 
combined with low-dose CsA (half the dose that produces 
nephrotoxicity in their model), SRL resulted in changes in 
renal structure and function similar to the changes observed 
with full-dose CsA. 
Pharmacokinetic interaction
The major explanation for the enhancement of CsA 
nephrotoxicity by SRL is a pharmacokinetic interaction. SRL 
is thought to increase the exposure to CsA. This hypothesis 
was supported by the observation that significantly lower 
CsA doses were required to achieve whole-blood targeted 
concentrations among SRL-treated patients than AZA-treated international Journal of Nanomedicine 2006:1(3) 274
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patients in the US pivotal trial. The hypothesis of a local 
interaction within the kidney between SRL and CsA was 
suggested. Napoli et al (1997) demonstrated in a rat model 
that a pharmacokinetic interaction between SRL and CsA 
increased the whole-blood and, especially, the renal-tissue 
concentrations of each agent. More recently, a second study 
by Podder et al (2001) confirmed these results. A salt-depleted 
rat model was used to dissect the pharmacokinetic component 
of the toxicity produced by CsA–SRL combination. At each 
CsA dose level, concomitant administration of SRL produced 
a significant pharmacokinetic interaction, increasing further 
the CsA concentration by approximately 2-fold above that 
found in hosts treated with CsA alone. They also found 
that at each CsA dose level, intra-renal CsA concentration 
increased when animals were also treated with SRL. It may 
be hypothesized that a pharmacokinetic interaction between 
SRL and CsA may alter CsA exposure, more importantly 
within the kidney cells than in the blood. 
The mechanisms and the targets of this interaction, 
which may ultimately affect SRL and/or CsA drug exposure, 
are largely unknown. However, the cytochromes P450 3A 
(CYP3As) isozymes and the P-glycoprotein (P-gp) are 
candidates, since CsA and SRL share common metabolic and 
transport pathways by these proteins. Recent data suggest that 
P-gp may be especially involved in the SRL–CsA interaction. 
SRL and CsA are both substrates for P-gp, the product of 
the multi-drug resistance (MDR1 also called ABCB1) gene. 
Since P-gp acts as a transmembrane efflux pump involved 
in energy-dependent export of xenobiotics from inside the 
cells, it is thought that P-gp plays a central role in cellular 
detoxication. Using an in vitro model of normal human 
renal epithelial cells (HRECs) in primary culture, we have 
shown that CsA exhibited a cytotoxic effect on HRECs in a 
concentration-dependent manner and that P-gp inhibition led 
to a significant increase of CsA cellular concentration and to 
a increase of its cytotoxicity (unpublished data). 
Another hypothesis implicates TGF-β1 which is a 
well known factor in the pathophysiology of chronic CsA 
nephrotoxicity. There is evidence to suggest that SRL can 
independently increase TGF-β1 expression in renal proximal 
tubular epithelial cells (Swinford et al 2002). Moreover, 
it has been shown that patients treated with SRL have an 
enhanced production of TGF-β1 and type III collagen early 
after kidney transplantation (Oliveira et al 2002; Saunders 
et al 2003). In a salt-depleted rat model of CsA chronic 
nephrotoxicity, Shihab et al (2004b) used low doses of CsA 
to examine the impact of SRL co-administration on kidney 
structure and function and on the expression of TGF-β1, PAI-
1, and ECM proteins in the kidney. They demonstrated that 
SRL alone significantly increased TGF-β1 production and 
potentiated TGF-β1 production by 3-fold in combination with 
low-dose CsA. Using 2 doses of CsA in combination with 
SRL, Shiab et al showed that SRL in combination wih low 
doses of CsA was associated with a significant augmentation 
of TGF-β1 production and that the net result was a TGF-β1 
expression that was similar to what was observed with full 
doses of CsA. 
Finally, the role of apoptosis has been investigated. Using 
a mouse model, Lieberthal et al (2001) showed that SRL 
increases the apoptosis of renal tubular epithelial cells. The 
induction of pro-apoptotic genes may impair the ability of 
the kidney to remodel effectively in response to injury. As a 
result, SRL, when associated with CsA, may inhibit tissue 
repair not only by this proapoptotic effect but also by its 
antiproliferative effect.
Short and long-term effects of 
early CsA withdrawal in presence 
of SRL 
Feasibilty of CsA withdrawal with SrL 
in stable patients
A systematic review of CNIs has been published recently 
(Mulay et al 2005). We will focus on the 5 studies which 
used CsA, one of them having been published several 
times according to the length of the follow-up (Johnson 
et al 2001; Gonwa et al 2002; Baboolal 2003; Stallone 
et al 2003; Jardine 2004). Most trials involved low-risk 
patients with a large proportion of Caucasians, very few 
diabetics, and the majority of patients undergoing primary 
transplantation. Only 1 study was performed in the US, with 
the remainder from Canada, Europe, and Australia. Delayed 
graft function and highly sensitized patients were sometimes 
used as noninclusion criteria of some patients. Most trials 
also required that the patient had adequate and stable renal 
function with no significant acute rejection in the preceding 
month. The characteristics of the studies are summarized in 
Table 1.
The first study, the so-called Tricontinental study, came 
from a group of 57 renal transplantation centers in Europe, 
Canada, and Australia (Johnson et al 2001; Oberbauer, 
Kreis, et al 2003; Kreis et al 2004; Oberbauer et al 2005). 
The patients enrolled in this prospective, randomized, open-
label trial received SRL, CsA, and steroids up to the time 
of randomization at month 3 after transplantation. In this 
study, to be randomized, patients had to have experienced no international Journal of Nanomedicine 2006:1(3) 275
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grade 3 acute or vascular rejection during the 4 weeks before 
randomization, and to have a serum creatinine level that never 
exceeded 400 mmol/L. In all, 525 patients were enrolled 
but only 430 (82%) met the criteria for randomization at 
3 months. In another recent controlled, randomized study 
(Gonwa et al 2002), 246 renal transplant recipients were 
enrolled, and 197 of them were randomly assigned to receive 
either conventional-dose CsA combined with 2 mg/day SRL 
(n = 97) or reduced-dose CsA with concentration-controlled 
SRL, at doses adjusted to maintain trough concentration 
levels of 10–20 ng/mL (n = 100). Among them 49 were not 
randomized because of the absence of renal function recovery 
by 48 hours post surgery. Patients in the CsA reduced-dose 
group were eligible for CsA withdrawal if their renal function 
was stable at the end of month 2 after transplantation, if they 
had not been treated for acute rejection in the preceding 
3 weeks, and if their SRL trough concentrations were 
10–20 ng/mL. A total of 82 patients were eligible for CsA 
elimination. This maneuver was successfully completed 
in 76 patients among 246 initial patients. Overall, CsA 
withdrawal was completed in 78–93% of randomized patients   
(Table 1). 
Regarding the regimen used to withdraw CsA, in the 
Tricontinental study, patients were randomly assigned, either 
to remain on triple-drug therapy including SRL (trough levels 
> 5 ng/mL) and CsA (trough levels: 75–200 ng/mL), or to 
CsA withdrawal. Those in the withdrawal group had their 
daily SRL dose adjusted to maintain trough concentrations of 
20–30 ng/mL, and the CsA dose was gradually decreased and 
then eliminated over 4–6 weeks. The median CsA elimination 
period was 41 days (Johnson et al 2001). In the bicontinental 
study, CsA was withdrawn completely during the third month 
after transplantation (25% dose reduction per week for 4 
weeks). At month 12, the mean daily dose of SRL in the latter 
group was 6.45 ± 0.43 (Gonwa et al 2002).
Graft and patient survival
CsA withdrawal had no effect on patient death. In the 
Tricontinental study, patient survival was similar between 
groups. After 48 months of follow-up, this survival was 
95.3% in the CsA elimination group vs 92.1% (p = 0.232) 
(Oberbauer et al 2005). Interestingly, during the same 
follow-up, the incidence of malignancies was lower in the 
elimination group (7.4% vs 12.1%, p = 0.14).
Regarding graft survival, all the studies report in the 
short term the absence of difference between patients in the 
withdrawal group compared with patients still receiving CsA. 
The most stiking data come from the long-term follow-up of 
the Tricontinental study (Oberbauer et al 2005). The results 
after 48 months have been reported recently. In this study, 
the primary endpoint was noninferiority of graft survival in 
Table 1  Demographic characteristics of CsA withdrawal studies
Characteristics  Johnson et al  Gonwa et al  Baboolal  Stallone et al  Jardine
  (2001)  (2002)  (2003)  (2003)  (2004)
Year  2001  2002  2003  2003  2004
Sample size  215/215  100/97  42/45  20/20  10/105
Primary transplant (%)  90/92  100/100  Nr  Nr  Nr
Caucasian (%)  94/95  80/73  93/98  100/100  Nr
Diabetes (%)  8/7  8/9  5/0  Nr  Nr
Deceased donor (%)  88/88  100/100  85/91  100/100  Nr
Mean donor age (years)  42/44  Nr  Nr  40/46  Nr
Follow-up  12
a  12  6  12  12
Criteria for CsA  Cr <  400  Stable  Cr <  400  Nr  Nr
withdrawal
exclusion criteria  Planned  DGF  > 7 days  Planned  Nr  Nr
  antibody  repeat transplant  antibody
  induction  or live donors  induction
Time of withdrawal   3  2  3  3  3 
post-transplantation (months) 
Complete withdrawal (%)  93  78  81  Nr  Nr
Adapted from Mulay et al (2005).
aPublished follow-up at 48 months (Oberbauer et al 2005).
Abbreviations: Cr, creatinine; DGF, delayed graft function; Nr, not reported. 
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the CsA elimination group. Indeed the graft survival was 
not inferior. Because of the figures observed on the 95% 
confidence interval (difference –11.2%, CI = –18.5, –3.8), 
it is possible to conclude that graft survival was superior in 
the elimination group. This survival was better both when 
death with a functioning graft was included (91.5% vs 
84.2%, p = 0.024) or when it was censored (96.1% vs 90.6%, 
p = 0.026). However, the major drawback of this study is that 
the association of SRL and CsA as the control group is not 
optimal and that it is difficult to draw any clear conclusion 
in the long term, since most patients in the control group 
were not receiving the protocol regimen during all the study 
period. 
Acute rejection
Regarding the risk of acute rejection after CsA withdrawal 
in the context of SRL treatment, there was a constant 
trend toward a higher incidence following CsA withdrawal 
(Mulay et al 2005). The pooled estimate including the trial 
with TAC showed a significant increase in the risk of acute 
rejection. The absolute risk difference was 6.0%. In the 
Tricontinental study, withdrawal was associated with a small 
but significant increase in the incidence of acute rejection. 
After randomization at 3 months post-transplantation, 
9.8% of the patients in the withdrawal group experienced a 
biopsy-proven acute rejection episode versus 4.2% of those 
who continued on CsA (p = 0.035) (Johnson et al 2001). 
This increase seems to appear during the early period after 
CsA withdrawal, especially in patients with low SRL trough 
concentrations. Indeed, very few rejections occurred after 
the first year. After 48 months of follow-up, the incidence 
of acute rejection after randomization was 10.2% in the 
elimination group vs 6.5% in the control group (p = 0.223) 
(Oberbauer et al 2005). 
Renal function
Renal function was assessed in all studies using serum 
creatinine and calculated creatinine clearance. In all studies, 
CsA withdrawal was associated with a significant increase 
in the creatinine clerance (weighted mean difference of 
7.78 mL/min, p < 0.001) and a significant lower serum 
creatinine (weighted mean difference –0.19 mg/dL, p < 0.001) 
(Mulay et al 2005). 
In the Tricontinental study, this difference was observed 
as early as one month after randomization. The GFR 
progressively improved during month 12 in the CsA 
withdrawal group. Although some patients who remained on 
CsA also improved, a larger proportion improved in the CsA 
withdrawal group (72.2% vs 40.4, respectively, p < 0.001). 
When patients were grouped according to baseline serum 
creatinine (ie, last value measured before randomization), all 
groups potentially benefit from CsA elimination at 3 months, 
irrespective of their serum creatinine level at this time (Mota 
et al 2004). These results have been recently confirmed (Russ 
et al 2005). The benefit was more marked in patients with a 
baseline calculated GFR of less than 45 mL/min. On the other 
hand, more than 25% of the patients in the CsA withdrawal 
group experienced no improvement in renal function. After 
2 years of follow-up, serum creatinine was still significantly 
lower in the CsA-withdrawal group. One important finding 
in this study is the long-term follow-up (up to 48 months) 
which has been recently reported (Oberbauer et al 2005). 
This improvement is still observed even after a long follow-
up. Using the calculated GFR, the slope was significantly 
negative in the intent-to-treat (ITT) analysis for the CsA 
maintenance group (–2.71 mL/min/year, p < 0.001) and was 
positive in the CsA elimination group (0.53 mL/min/year, 
p = 0.151). The difference between slopes was statistically 
significant (–3.24 mL/min/year, p < 0.001) in favour of the 
CsA elimination group.
In another study, at 12 months, renal function assessed by 
serum creatinine and calculated GFR values using Nankivell’s 
formula  had improved significantly in the CsA withdrawal 
group. This improvement was greater in the patients who had 
remained rejection-free, but was still significant when those 
who experienced a rejection were included in the analysis. 
Unfortunately, specific information on renal function in the 
“rejector”-group is not available (Gonwa et al 2002). 
Renal pathology
Various studies including the one from Nankivell have 
demonstrated the value of protocol biopsies to determine the 
true incidence of chronic allograft nephropathy, to detect early 
signs of such chronic damage, and to differentiate between 
chronic rejection and CNIs nephrotoxicity (Nankivell et al 
2003). Pathologic allograft lesions have been evaluated in 2 
different studies.
Ruiz et al (2004) have analyzed pretransplant and 1-year 
renal allograft biopsies from 64 patients enrolled in the 
Tricontinental study. A higher proportion of patients showed 
progression of chronic interstitial (ci), tubular (ct), and 
vascular (cv) lesions in patients with CsA continuation (70% 
vs 40.9%, 70% vs 47.8%, and 29.4% vs 25%, respectively). 
However, progression of chronic glomerular lesions and 
arterial hyalinosis was not different between the groups. 
When the Banff chronicity index was used, progression was international Journal of Nanomedicine 2006:1(3) 277
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present in 76.5% of patients in CsA continuation vs 31.3% 
in the CsA elimination group (p = 0.01) (Racusen et al 1999). 
Similar results were found when using another classification 
of chronic lesion (CADI score) (Isoniemi et al 1994), with 
more frequent progression of both interstitial fibrosis (F) and 
tubular atrophy (T). Finally, using the Banff classification, 
the diagnosis of chronic allograft nephropathy (CAN) (any 
grade) at 1 year was higher, but not statistically in the group 
of patients remaining on CsA (70.8% vs 59.3%, p = 0.25).
The results from the whole Tricontinental population 
were reported elsewhere (Mota et al 2004). Two pathologists 
blindly evaluated 484 biopsies performed at engraftment 
and at 12 and 36 months after transplantation. The results 
are shown in Table 2. The global analysis of all patients 
with biopsy readings shows that the mean CADI score at 
36 months was significantly lower in the CsA elimination 
group (4.70 vs 3.20, p = 0.003). This was also true for the 
mean tubular atrophy score (0.77 vs 0.32, p < 0.001). All 6 
components of the CADI score were numerically lower in 
the CsA elimination group. Furthermore, inflammation and 
tubular atrophy scores decrease significantly between 12 
and 36 months. 
Stallone et al (2003) report the results of routine biopsies 
in 40 patients at 12 months after transplantation. CAN was 
diagnosed in 55% of all patients, of whom 64% were in the 
CsA continutation group and 36% in the CsA elimination 
group. These findings were even more notable when moderate
to severe lesions were analyzed (respectively 90% vs 32%) 
and for vascular lesions (90% vs 38%). 
Risk of malignancy
As already stated, SRL, in contrast to CsA or TAC, has been 
shown to inhibit rather than promote cancer in experimental 
models. SRL alone, or combined with CsA, prevented 
metastatic tumor progression and prolonged survival of 
mice inoculated with either mouse renal cancer or human 
T24 human bladder cancer (Luan et al 2002). Additionally, 
SRL alone or plus CsA reduced the number of human 
renal cell carcinoma metastases in SCID mice, whereas 
CsA alone increased the number of metastases (Luan et 
al 2003). In humans, 2 recent studies have reported very 
important data on this matter. First, Kauffman et al (2005) 
have analyzed the post-transplant malignancies reported in 
the Organ Procurement and Transplantation Network (OPTN) 
among 33249 renal transplant recipients. In a multivariate 
analysis, the relative risk associated with mTOR inhibitors 
immunosuppression for any de novo cancer was 0.39 
(p = 0.0002) or for de novo solid cancer was 0.44 (p = 0.0092). 
Finally, Campistol et al (2006) reported the risk of developing 
cancer in the Rapamune Maintenance Regimen trial. At 5 
years, the median time of a first skin carcinoma was delayed 
(491 vs 1126 days, p = 0.007) and the risk of an event was 
significantly lower (relative risk 0.346, p < 0.001). The risk 
of both basal and squamous cell carcinomas and nonskin 
cancer were reduced (9.6% vs 4.0%, p = 0.032). 
Table 2  Chronic lesions assessed by the Chronic Allograft Damage index (CADi) score
  Baseline  12 mo  36 mo
  CsA  CsA  CsA  CsA  CsA  CsA
  continuation  withdrawal  continuation  withdrawal  continuation  withdrawal
All patients           
Mean ± SD  1.27 ± 1.37  1.23 ± 1.36  3.56 ± 1.92  3.45 ± 1.79  4.39 ± 1.84  3.59 ± 1.98
N  97  82  95  86  47  48
Bx BL–12 mo           
Mean ± SD  1.27 ± 1.38  1.15 ± 1.35  3.64 ± 1.82  3.63 ± 1.82   
N  79  68  79  68   
Bx BL–36 mo           
Mean ± SD  1.17 ± 1.51  1.02      4.50 ± 1.94
a  3.32 ± 1.24
a
N  40  37      40  37
Bx 12–36 mo            
Mean ± SD      3.62 ± 2.04  3.50 ± 1.65  4.55 ± 1.92  3.63 ± 2.02
N      35  42  35  42
Bx BL 12 and 36 mo           
Mean ± SD  1.26 ± 1.60  0.99 ± 0.92  3.74 ± 1.84  3.53 ± 1.66  4.70 ± 1.86
a  3.20 ± 1.85
a
N  31  32  31  32  31  32
Adapted from Mota et al (2004).
ap < 0.005 ANCOvA
Abbreviations: BL, baseline; Bx, biopsy; mo, months.international Journal of Nanomedicine 2006:1(3) 278
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Adverse events profile
Hypertension
Some of the adverse events were less frequent in the CsA 
withdrawal group. CsA withdrawal was associated in all 
studies with a significant reduction in the risk of hypertension 
(relative risk 0.56, p < 0.001) and with a significant decrease 
of both systolic and diastolic blood pressure (Mulay et al 
2005). 
This was demonstrated specifically in the Tricontinental 
study (Johnson et al 2001). Hypertension was reported in 
7.0% of the patients in the withdrawal group vs 16.3% in the 
triple therapy group. In addition, both diastolic and systolic 
blood pressure were significantly lower in the CsA withdrawal 
group (–3 mmHg and  –6 mmHg, respectively) despite 
significantly less frequent use of antihypertensive medication 
in this group. At 2 years, systolic blood pressure remained 
significantly lower in the CsA withdrawal group (Oberbauer, 
Kreis, et al 2003). These differences were still present after 
48 months of follow-up (Oberbauer et al 2005).
Lipids profile
Another question is the lipid profile of these patients. After 
randomization and high dose SRL, a transient increase 
in serum triglycerides averaging about 0.4 mmol/L was   
observed (Oberbauer et al 2005). However, there was no 
difference between the CsA withdrawal and continuation 
groups for mean concentrations of total cholesterol, calcu-
lated LDL cholesterol, HDL cholesterol, and triglycerides. 
Noteworthy, in the 2 groups, which both continued with SRL, 
70% of patients were taking statins and 23%, fibrates. When 
all the studies are pooled together, CsA elimination was not 
associated with any significant effect on total cholesterol or 
triglyceride. However, there was a trend toward more statin 
use in the CsA elimination group. 
Quality of life
Health-related quality of life was specifically compared in 
SRL-treated kidney transplant patients after CsA elimination 
and in patients who were still treated with CsA at 2 years in 
the Tricontinental study (Oberbauer, Hutchison, et al 2003). 
Of the 361 patients studied, those in the CsA-withdrawal 
group improved significantly more than others, according 
to the replies in the “Kidney Transplant Questionnaire” 
(KTQ) (Laupacis et al 1993; Jacobs et al 1998) fatigue and 
appearance domains. SF-36 vitality score was also better 
in the CsA-withdrawal group. The authors reported an 
improvement in the fatigue and appearance scores but no 
differences in physical symptom scores. Other important 
findings are the consistent treatment differences on measures 
of fatigue and vitality. From month 3 after transplantation (the 
time of randomization) the patients in the CsA elimination 
group reported further improvements in fatigue whereas in 
the CsA continuation group, patients still reported increase in 
fatigue. These differences in the health related quality of life 
and the SF36 vitality scores are considered to be clinically 
meaningful. 
various side-effects
CsA withdrawal was associated with improved uric acid 
and magnesium levels. On the other hand, SRL has been   
associated with other adverse events. Indeed, in the CsA 
withdrawal group treated with high trough SRL levels, 
more thrombocytopenia, hypokaliema, and abnormal liver 
function test were reported (Johnson et al 2001). In other 
studies, SRL-related side-effects, such as thombocytopenia, 
abnormal liver function tests, hypokaliemia, ileus, abnormal 
wound healing, infectious pneumonia, and stomatitis were 
more frequent in patients randomized to CsA withdrawal. 
It is, however, difficult to assess precisely this risk since 
patients in both the treatment and in the control groups were 
receiving SRL.
Discussion and conclusions 
Although CsA has been associated with a constant 
improvement in the results of renal transplantation, its 
use is also responsible for various short- and long-term 
toxicities, including nephrotoxicity, and for the worsening of 
cardiovascular risk factors. Another potential benefit might 
be a lower risk of long-term cancer, because low-dose CsA 
has already been linked to the development of carcinologic 
complications. Futhermore, concomitant use of CsA and 
SRL is associated with an increased risk of nephrotoxicity. 
On the other hand, SRL use may have a potential effect 
on tolerance induction, decreased fibrosis associated with 
chronic allograft dysfunction, and anti-tumoral effect. 
Therefore, it is important to assess the best way to use this 
immunosuppressive agent after organ transplantation. After 
CsA withdrawal, SRL seems to be associated with better 
prevention of acute rejection episodes than mycophenolate 
mofetil, since the increase of the incidence of such rejection 
when CsA was withdrawn 3 months after transplantation 
was not statistically significant. To identify the regimen that 
achieves the most beneficial metabolic outcomes, it is clear 
that prospective, randomized studies in which SRL-steroids 
are compared with MMF-steroids as maintenance therapy are international Journal of Nanomedicine 2006:1(3) 279
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of major importance for renal transplantation. One important 
point, when considering the results from the Rapamune 
Maintenance Regimen trial (Oberbauer et al 2005), is that the 
SRL blood concentration target levels are higher than the one 
used nowadays. It is well known that since the introduction 
of CsA in the early 1980s, much has been learned about 
the use of immunosuppressive treatments. This knowledge 
often leads to a decrease in drug dosage and therefore an 
improvement of the possible side-effects. 
The next problem is to define the population of patients 
that can benefit from CsA withdrawal. It is noteworthy that 
in the SRL trial, only 82% of the patients were eligible for 
CsA withdrawal 3 months after transplantation. In both the 
MMF and the SRL trials, CsA was effectively withdrawn 
from 93% and 97% of patients, respectively. 
Finally, besides CsA withdrawal, there is increased   
interest in the design and implementation of avoidance 
protocols, ie, immunosuppressive regimens designed to 
avoid treatment with CsA or eliminate it completely. The 
major disadvantage of CsA sparing or withdrawal is that 
patients must be exposed to CsA in the first place. There 
is evidence that CsA-associated renal toxicity may occur 
early, and progress in the native kidney of pancreas and 
lung transplant recipients and in patients with uveitis, even 
after dose reductions. Another concern is the effect of 
calcineurin inhibitors on the induction of immune tolerance. 
CNIs have been shown to limit T-cell activation by blocking 
susceptibility to apoptosis and activation-induced cell 
death. Many preliminary studies of CsA avoidance have 
been reported. Flechner et al (2002) have administered a 
combination of anti-CD25 antibody, MMF, steroids, and 
SRL, a regimen that provided comparable 1-year patient and 
graft survival. In addition, at 1 year, the incidence of acute 
rejection episodes reaches an impressive 6.4% compared 
with 16.6% in the controls on a CsA-based regimen. Renal 
function, measured by the creatinine clearance, was also 
significantly better in the CsA-free group (81.1 mL/min vs 
61.1 respectively) and did not tend to worsen during the first 
year after transplantation. 
In any case, not all patients could benefit from these 
new approaches and new concepts, which more than ever 
illustrate the need for immunological and nonimmunological 
markers to enable immunosuppression to be tailored to the 
requirements of specific patient populations.
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